drugset / Trial / NCT00141479
To Evaluate the Impact of Treatment Interruption on Re-initiation of Bifeprunox
Phase 2
Completed
Solvay Pharmaceuticals
H. Lundbeck A/S · collabWyeth is now a wholly owned subsidiary of Pfizer · collab
RandomizedSingle-groupDouble-blindTreatment
Summary
The purpose of this study is to investigate a safe treatment interruption interval(s) for re-initiation of bifeprunox at a therapeutic dose. The study duration is approximately 7 to 10 weeks.
Timeline
- Start
- 2005-05
- Primary completion
- 2006-11
- Completion
- 2006-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bifeprunox | Small molecule | — | — |